bbert p16 and p15, 2 inhibitors of cyclin-dependent kinases, are frequently hypermethylated in hematologic neoplasias. Decitabine, or 5-Aza-2-deoxycytidine, reverts hypermethylation of these genes in vitro, and low-dose decitabine treatment improves cytopenias and blast excess in ϳ50% of patients with high-risk myelodysplastic syndrome (MDS). We examined p15 and p16 methylation status in bone marrow mononuclear cells from patients with high-risk MDS during treatment with decitabine, using a methylation-sensitive primer extension assay (Ms-SNuPE) to quantitate methylation, and denaturing gradient gel electrophoresis (DGGE) and bisulfite-DNA sequencing to distinguish individually methylated alleles. p15 expression was serially examined in bone marrow biopsies by immunohistochemistry. Hypermethylation in the 5 p15 gene region was detected in 15 of 23 patients (65%), whereas the 5 p16 region was unmethylated in all patients. Among 12 patients with hypermethylation sequentially analyzed after at least one course of decitabine treatment, a decrease in p15 methylation occurred in 9 and was associated with clinical response. DGGE and sequence analyses were indicative of hypomethylation induction at individual alleles. Immunohistochemical staining for p15 protein in bone marrow biopsies from 8 patients with p15 hypermethylation revealed low or absent expression in 4 patients, which was induced to normal levels during decitabine treatment. In conclusion, frequent, selective p15 hypermethylation was reversed in responding MDS patients following treatment with a methylation inhibitor. The emergence of partially demethylated epigenotypes and re-establishment of normal p15 protein expression following the initial decitabine courses implicate pharmacologic demethylation as a possible mechanism resulting in hematologic response in
Introduction
The 5-methylcytosine distribution patterns in DNA are frequently altered during cellular transformation. 1 CpG island hypermethylation can coexist with global or gene-specific demethylation in malignant cells, [2] [3] [4] [5] resulting in transcriptional inactivation ("silencing") if it occurs in a promoter region. Expression of tumor suppressor genes (TSG) containing CpG-rich islands can be down-regulated by de novo methylation in primary tumors in vivo. 1, [5] [6] [7] Several TSGs altered by hypermethylation encode genes involved in cell cycle regulation (eg, Rb, p16, p15, VHL). Inactivation of TSGs by hypermethylation thus provides a novel therapeutic opportunity based on restoration of gene function and growth control in malignant cells by induction of demethylation.
5-Azacytidine and 5-Aza-2Ј-deoxycytidine (decitabine), 2 potent inhibitors of cytosine methylation, 8 have shown strong antileukemic activity 9 in acute myeloid leukemia (AML). In addition, both induce trilineage responses in myelodysplastic syndromes (MDS) at dose levels allowing for outpatient management, with moderate myelotoxicity and no significant nonhematologic toxicity. In a recent report of a clinical phase 3 study, 5-Azacytidine altered the natural course of MDS. 10 Decitabine results in a 49% to 53% hematologic and a 31% cytogenetic response rate in high-risk MDS. [11] [12] [13] Activity of demethylating agents in myeloid malignancies may hypothetically be due to induction of differentiation, 14 cytotoxicity, 15 or changes in the rate of apoptosis. Conceivably, these pathways could be triggered by up-regulation of eg, growth-control genes silenced via hypermethylation.
p15, a target of transforming growth factor-␤ signaling, 16 is an inhibitor of the cyclin-dependent kinase-4 17, 18 and a negative regulator of the G 1 /S progression within the cell cycle. 19 p15 is highly homologous to and colocalized with p16 within a ϳ25-kb region on the short arm of human chromosome 9. Unlike in solid tumors, the 5Ј region of p15 but not p16 is frequently methylated in AML 5, 7 and MDS. 20, 21 Selective p15 hypermethylation was also observed in a mouse model of radiation-induced malignant lymphoma. 22, 23 To determine whether the hypermethylated 5Ј region of p15 was demethylated in MDS patients undergoing low-dose decitabine treatment, we examined it in 23 patients.
A methylation-sensitive single nucleotide primer extension (MsSNuPE) assay was used, since it is quantitative even when measuring a low degree of methylation. 24, 25 To address whether partially demethylated epigenotypes are newly generated during treatment (indicative of allele-specific hypomethylation), denaturing gradient gel electrophoresis and sequence analyses were performed. Immunohistochemistry for p15 protein was performed on bone marrow cells with p15 hypermethylation. Reversal of p15 hypermethylation in responding MDS patients was associated with partially demethylated epigenotypes and induction of p15 re-expression. Hypermethylated p15 (and other methylated genes) may be a therapeutic target of the DNA methylation-inhibitory activity of decitabine in MDS.
Patients, materials, and methods

Patient samples
Bone marrow mononuclear cells (MNCs) were collected from MDS patients before and during treatment with decitabine (kindly provided by Pharmachemie B.V., Haarlem, The Netherlands) within a phase 2 study 12 approved by the local ethics committee, after obtaining informed written consent. Samples from 23 patients (10 men and 13 women, median age, 65 years; range, 52-80 years) were analyzed prior to treatment and when bone marrow studies were done according to study protocol or clinical course. Control samples included peripheral blood lymphocytes (PBLs) and bone marrow MNCs from healthy donors, CD34 ϩ -enriched normal peripheral blood progenitor cells from patients with breast cancer, leukemic blasts from a patient with chronic myelogenous leukemia (CML), and sperm DNA.
Hematologic responses of the decitabine-treated MDS patients were defined as described 12 : complete remission was defined as a normocellular or slightly hypocellular marrow with fewer than 5% blasts and hemoglobin (Hb) level higher than 11 g/dL; granulocyte numbers higher than 1.0 ϫ 10 9 / L; and platelet count greater than 100 ϫ 10 9 /L. Partial remission was defined as a greater than 50% decrease in the number of bone marrow myeloblasts and a trilineage response (increase in Hb level by more than 2 g/dL, in platelet count by more than 50 ϫ 10 9 /L, and in granulocyte count by more than 1.0 ϫ 10 9 /L). Hematologic improvement was defined as an improvement of 1 to 3 lineages of the peripheral cell counts but not enough to qualify for a partial remission. 12 Blast reduction was defined by at least a 20% reduction relative to the initial bone marrow blast count in case of blast excess. Stable disease was defined by the absence of complete remission (CR), partial remission (PR), hematologic improvement, or blast reduction but without clear disease progression.
Ms-SNuPE analysis
Two micrograms of DNA (isolated using standard protocols) was digested with EcoRI (Boehringer Mannheim, Indianapolis, IN) and treated with sodium bisulfite for 16 hours as described. 26 Methylation analysis was performed using the methylation-sensitive single nucleotide primer extension (Ms-SNuPE) assay. 24, 27 Primers have been described. 27 Polymerase chain reactions (PCRs) for the p15 and p16 promoters were performed in 25 L total volume under conditions described previously. 27 PCR products were gel-purified (QiaQuick; Qiagen, Valencia, CA), and the template was resuspended in 20 to 40 L volume of H 2 O. Ms-SNuPE reactions were performed in a 10 L volume, and 50 to 100 ng of DNA was incubated in a final concentration of 1 ϫ PCR buffer, 27 p15 methylation (given in percentages below the C lanes) was determined by quantifying the radioactive signal incorporated into the 3 labeled primers during the primer extension step of Ms-SNuPE. Counts were measured using a phosphorimager. The average of the 3 CpG sites was calculated, subtracted from the lane background, and expressed as a C/C ϩ T ratio.
Bisulfite-DGGE analysis
Collective amplification of methylated and unmethylated p15 alleles (between positions Ϫ47 and ϩ215 relative to the transcription start site) was performed by a PCR reaction using previously described guaninecytosine (GC)-clamped primers. 28 PCR was carried out in a final volume of 25 L containing 100 to 200 ng bisulfite-treated DNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 0.2 mM cresol red, 12% sucrose, 0.2 mM each dNTP, 0.4 M each primer, and 0.8 units of AmpliTaq polymerase (Perkin-Elmer Cetus, Gaithersburg, MD). The PCR reaction was initiated by "hot start," followed by 39 cycles at 94°C for 20 seconds, 55°C for 20 seconds, and 72°C for 30 seconds, and a final extension at 72°C for 5 minutes. Normal peripheral blood cells (normal PBCs) and in vitro methylated DNA served as negative and positive controls, respectively. Fifteen microliters of the PCR product was loaded onto a 10% denaturant/6% polyacrylamide-70% denaturant/12% polyacrylamide doublegradient gel (100% denaturant ϭ 7 M urea and 40% formamide). The gel was run at 110 V for 16 hours in 1 ϫ Tris acetate/EDTA (ethylenediaminetetraacetic acid) buffer at 56°C, methylated alleles migrate farther than unmethylated alleles. The gel was stained with ethidium bromide and photographed under UV transillumination.
Bisulfite genomic sequencing
For subcloning and sequencing of individual alleles, bisulfite-treated genomic DNA was amplified with primers for the 5Ј region of p15 (as described above) or exon 2 of p16, respectively. 29 Purified PCR products were subcloned using the TA cloning kit (Invitrogen, San Diego, CA). Individual clones were grown and DNA was prepared using mini-prep kits. Up to 10 individual clones of each bisulfite preparation were subjected to automated sequencing in both directions using an ABI Sequencer (Foster City, CA).
Immunohistochemistry
Serially obtained, calcium acetate glutaraldehyde formaldehyde (CGF)-fixed, paraffin-embedded tissue sections from 5 healthy individuals (bone marrow donors) and 10 patients with p15 hypermethylation were incubated with a polyclonal anti-p15 antibody (K-18; Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:75 as described. 30 3-amino-9-ethylcarbazole served as chromogen using the avidin-biotin method (Vectastain ABC kit; Vector Laboratories, Burlingame, CA). Sections were counterstained with Meyer hemalaun (Sigma). Staining of myeloid precursors was scored semiquantitatively by visual inspection for 3 categories: Ϫ, completely negative or only few dispersed positive cells; ϩ, a moderate number of cells stained positive; ϩϩ, the majority or all cells stained positive.
Simultaneous detection of p15 and CD34 protein on bone marrow biopsies was achieved by double-staining with p15 antibody (labeled by the avidin-biotin complex method) and human CD34 monoclonal antibody QBEND10 (Immunotech, Marseille, France) labeled by alkaline phosphatase antialkaline phosphatase (APAAP) method as described. 31 
Results
Hypermethylation of the p15/INK4B 5 region is frequent in high-risk MDS
Bone marrow MNCs from 23 patients with intermediate/high-risk MDS 32 were analyzed for p15 methylation prior to decitabine treatment. Three CpG nucleotides within a 170-bp region extending into p15 exon 1 and part of a CpG island were subjected to Ms-SNuPE analysis. Normal peripheral blood and bone marrow MNCs exhibit between 1% and 10% methylation of the 5Ј regions of p15 and p16. 24, 27 A conservative, arbitrary cutoff of 15% methylation was therefore chosen to define hypermethylation. p15 methylation of greater than 15% was observed in 15 of 23 patients (median, 29%; range, 16%-54%, Table 1 ). Hypermethylation occurred in all French-American-British (FAB) subtypes and thus was not limited to the presence of excess bone marrow blasts. The p16 promoter region showed minimal hypermethylation in any patient (median, 3%; range, 1%-10%).
Reversal of p15 hypermethylation in MDS by decitabine treatment
Of 23 MDS patients receiving one or more courses of low-dose decitabine, 12 19 were evaluable for changes in p15 methylation, 2 had disease progression prior to start, one died prior to evaluation after course 1, and one had progressive cytopenia and declined a second bone marrow aspirate. As shown for a representative patient in Figure 1 , initial p15 hypermethylation (45%) was reduced to 33% following the first course of decitabine, with reduction to 12% after 3 subsequent courses. Of 12 patients with p15 hypermethylation prior to decitabine treatment, 9 showed at least a 25% decrease, to a median of 16% (range, 5%-34%). In one case, the decrease was less than 25%; in 2 cases, p15 methylation increased ( Figure 2 ). Patients without initial p15 hypermethylation showed no changes in methylation levels during continued treatment. Hematologic responses are given in Table 2 : p15 promoter hypermethylation was frequently reversed with response to decitabine treatment and associated with complete remissions, but was not a prerequisite for other hematologic responses (partial remission in patient 015).
Decitabine induces changes in the distribution of hypermethylated p15 epigenotypes in vivo
At the estimated steady-state serum levels of 0.1 to 0.5 M decitabine, [33] [34] [35] demethylation of several genes occurs in vitro 5, 23, [36] [37] [38] and in rodent models. 38 Bulk p15 demethylation during decitabine treatment may reflect emergence of normal hematopoietic progenitors with suppression of clonal cells, reduction of methylation in hypermethylated p15 alleles of clonal cells (depicted schematically in Figure 3 ), or a combination of both. Thus, 2 general mechanisms of action may be hypothesized: blast removal by selective cytotoxicity results in a reduction of the dysplastic clone and allows expansion of normal bone marrow precursor cells (Figure 3 , upper panel); or inhibition of maintenance methylation during each cell division leads to progressive exchange of methylcytosines for cytosines at individual alleles and, after several cell divisions, to a decrease in cells with highly methylated alleles and to expansion of normal hematopoietic cells (Figure 3, lower panel) .
Individual, clonotypic p15 epigenotypes can be detected by DGGE: migration distances of unmethylated, fully methylated, and partially methylated alleles differ with differences in melting temperatures. 28 Methylation at 27 CpG residues in a region of the 5Ј p15 gene that is nonoverlapping with the Ms-SNuPE amplicon was examined in bone marrow cells from 7 patients with p15 hypermethylation. Normal hematopoietic cells (bone marrow MNCs, CD34 ϩ -enriched peripheral blood progenitor cells [PBPCs], PBL) served as negative controls. Hypermethylation was observed in 6 of 7 MDS patients (ie, 87% concordance between DGGE and Ms-SNuPE). In 4 cases, distinct bands indicative of several partially methylated epigenotypes were detectable (shown for 2 patients in Figure 4 ). In the remaining 2 patients, hypermethylation appeared as an indistinct smear (not shown), similar to the heterogenous pattern of multiple epigenotypes described in AML. 28 Cells from patient 019 (panel A) and patient 013 (panel B) prior to treatment had diminished intensity of the top band (representing unmethylated alleles), compared to PBL control, and multiple bands representing partially methylated alleles. Following one course of treatment, this pattern was clearly altered, with novel, distinct bands closer to the top band, without significant reduction in bone marrow blast percentage. After 2 and more courses of 27 p15 methylation (given in percentages below the C lanes) was determined by quantifying the radioactive signal incorporated into the 3 labeled primers during the primer-extension step of Ms-SNuPE. Counts were measured using a phosphorimager. The average of all 3 CpG sites was calculated, subtracted from the lane background, and expressed as a C/C ϩ T ratio as described in "Patients, materials, and methods." Figure 2 . p15 methylation changes in MDS during treatment with decitabine. p15 methylation (averaged and given as percentage as described in legend to Figure  1 ) was plotted before and after treatment with decitabine, as well as at relapse for some patients. Results of treatment courses are plotted separately for 12 patients with initial p15 methylation of more than 15% (A). Methylation as determined after Ⅺ, 1 course of decitabine; OE, 2 courses of decitabine; f, 3 courses of decitabine; F, 4 to 6 courses of decitabine (where possible at evaluation of the final course). Reversal of p15 hypermethylation was defined as at least 25% reduction of methylation (relative to hypermethylation of more than 15% prior to treatment as given in Table 1 ). Thus, for the 7 patients with initial methylation of no more than 15%, reversal of hypermethylation was not measurable (NM). The total number of courses administered is given. Hematologic responses were defined as described in "Patients, materials, and methods." 12 Survival (in months) was from start of decitabine treatment (patients 001-021) or from diagnosis (patients 022, 023). For patient 001 at relapse and patient 018 during progression, p15 methylation was determined from peripheral blood MNCs because bone marrow MNCs were not available. ND indicates not done; -, no decitabine treatment; hematologic response not given because of early progression to AML (patient 022) and allogeneic transplantation as first line therapy (patient 023). Follow-up was until August 1, 2001. In the 2 healthy individuals, the 5Ј region of p15 was almost completely unmethylated in all alleles except for a single CpG in the 3Ј end of the cloned molecules, which was almost always methylated ( Figure 5A ). Individual p15 alleles of 3 MDS patients analyzed before decitabine treatment revealed a variable degree of methylated CpGs relative to all CpGs sequenced, averaging from 20% (patient 013, Figure 5B , upper rows) to 61% (patient 016, Figure 5C ) and 76% (patient 019, Figure 5D ). In each patient, the percentage of methylated moieties in individual alleles was reduced after the first course of decitabine treatment, to 10%, 39%, and 22%, respectively. At evaluation after 4 courses (patient 013, 016) and 6 courses (patient 019), methylation patterns in most or all alleles analyzed were identical to those of healthy individuals. Metaphase cytogenetics done at different treatment points revealed 100% abnormal metaphases before treatment in each patient. These were replaced by 100% (patient 013, 019) normal metaphases at the last time point analyzed ( Figure 5B-D, bottom rows) . Persistence of abnormal metaphases (100% in patient 013 and 019, 33% in patient 016) was noted after the first treatment course, when partially demethylated alleles were first detectable.
A comparative analysis was also performed on the p16 3Ј coding region. This region has been shown to both remethylate more readily than the p16 promoter region in vitro 39 and to be methylated to a variable degree in cells from leukemia patients. 29 A comparison of fully versus partially methylated alleles of p15 ( Figure 5D ) and p16 exon 2 ( Figure 5E ) after one course of treatment showed partial demethylation in the p15 5Ј region but not in the p16 exon 2 region of patient 019, also implying cytosine demethylation at individual alleles.
p15 expression is induced in myeloid precursor cells during decitabine treatment p15 hypermethylation is frequently associated with reduced or absent p15 expression in leukemic cells and cell lines. 23, [40] [41] [42] [43] We examined p15 expression immunohistochemically in fixedtrephine bone marrow biopsies. Among 5 healthy individuals, p15 positivity was scored in the majority of cells in 3 and in a moderate number of cells in 2. As previously described, 30 cytoplasmic p15 protein was predominantly detected in granulocyte precursor cells but not in erythroid cells and megakaryocytes (data not shown). p15 staining was then performed on serial biopsies from 10 MDS patients (shown for 2 patients in Figure 6A-B) . In 4 of 8 cases with p15 hypermethylation, cytoplasmic p15 expression was very low or absent prior to treatment, whereas in the other 4 patients and in 2 patients without hypermethylation, p15 levels were comparable to normal bone marrow ( Figure 6C ). Following 1 to 3 courses of decitabine, p15 expression was induced to high levels in all 4 patients with initially low or absent expression and persisted in the 6 patients with p15 expression prior to decitabine. Expression was For personal use only. on October 3, 2017. by guest www.bloodjournal.org From restricted to granulocyte precursor cells, and their abundance in the bone marrow did not change significantly with treatment ( Figure  6A-B) . Serial cytogenetics revealed persistence of the chromosomal abnormalities in all metaphases from patients 001, 005, and 018 with induction of p15 expression, suggesting that both p15 methylation and expression were altered in the same clone.
To address whether CD34 ϩ blasts show changes in p15 expression during treatment, double-staining of bone marrow biopsies against p15 and CD34 was done in 3 patients with excess of CD34 ϩ blasts. In each case, the majority of CD34 ϩ cells were negative for p15 (data not shown). This pattern did not change in sequential biopsies from 2 patients after 1 and 3 courses of decitabine (DAC), respectively, which had both persistence of CD34 cells and up-regulation of p15, indicating that p15 is not expressed by CD34 ϩ blasts but in more mature myeloid elements.
Discussion
Silencing of proliferation-associated genes by aberrant hypermethylation is commonly found in neoplasia. Reversion of p16 hypermethylation by 5-Aza-2Ј-deoxycytidine results in decreased proliferation and tumorigenicity of tumor cell lines and in animal models. 5, 23, 38, 39 Therefore, clinical application of DNA methylation inhibitors such as decitabine and 5-Azacytidine may influence gene-specific hypermethylation in vivo. We asked whether the clinical activity of decitabine in MDS was associated with DNA demethylation and reversal of silencing of the p15 gene, an inhibitor of G 1 /S progression. 18, 19 The choice of p15 was prompted by recent reports describing a greater than 50% incidence of hypermethylation in the 5Ј flanking region of p15 in MDS 20, 21 and AML, 5, 23, 28, 41 with decreased or absent p15 mRNA expression in 50% to 70% of primary AML samples. 42, 43 The present analysis confirmed hypermethylation of p15 upstream sequences in the majority of MDS patients, which was absent in normal hematopoietic precursor and mature cells, implying that p15 hypermethylation did not merely reflect an early maturation stage of the cells. Our results with 3 different methylation detection assays implicate 5Ј methylation of p15 as a regional 43 rather than site-specific phenomenon. The recruitment of corepressors and histone deacetylases to stretches of densely methylated sequences by MeCP2 44, 45 offers an explanation for the effect of a densely methylated CpG-rich regulatory region upon transcription.
Reversal of p15 hypermethylation was observed in 9 of 12 patients treated with decitabine and was associated with hematologic responses (including 3 CRs) in all 9 patients. Hematologic responses including one PR were seen in 4 of 7 patients lacking p15 hypermethylation, implying that other mechanisms may have been operative. Previous studies using other methylation assays described a close association between the percentage of bone marrow blasts in MDS and p15 hypermethylation. 20, 21 Since we determined the p15 methylation status in unsorted bone marrow MNCs, excess blasts might be the major source of hypermethylated p15 moieties. However, hypermethylation was also detectable in 4 of 7 patients with fewer than 5% bone marrow blasts (Table 1 ) and in peripheral blood MNCs not containing blasts (data not shown), suggesting that p15 methylation may be an early event preceding manifest blast expansion in MDS.
Kinetics of p15 methylation and blast percentage in the bone marrow during treatment showed emergence of fewer methylated alleles despite the persistence of blast excess and cytogenetic abnormalities. DGGE and direct sequencing of cloned molecules were indicative of induction of partial demethylation at individual alleles, as was lack of p16 exonic demethylation ( Figure 5E ). In 2 elegant studies also addressing the longstanding issue of pharmacological demethylation versus selection of methylated cells through cytotoxicity, increased globin expression in erythroid cells induced by 5-Azacytidine treatment was demonstrated on single erythroid colonies 46 and by in situ hybridization, 47 respectively. In the present study, immunohistochemistry was performed on serially obtained bone marrow biopsies with p15 hypermethylation. In 4 of 8 patients, abnormally low or absent p15 expression prior to treatment was up-regulated to levels found in normal bone marrow after 1 to 3 courses of decitabine and was paralleled by hypomethylation. Persistence of chromosomal markers provided further indication that demethylation occurred in cells of the abnormal clone and did not merely reflect emergence of nonclonal hematopoietic cells. Another study also described lack of p15 expression in the majority of clonal leukemic cells in the presence of high-density p15 methylation 43 ; however, p15 expression despite methylation of most alleles was also noted and discussed. The observed emergence of hypomethylated alleles with concurrent up-regulation of p15 expression in bone marrow cells provides the first example of gene-specific action of a demethylating antineoplastic agent in the clinical setting. However, demethylation of p15 (and other genes) during treatment with these agents does not necessarily mean that this is the main mechanism of action of this drug in vivo.
Nyce 48 investigated drug-induced DNA methylation changes using several antileukemic agents. In vitro exposure (adenocarcinoma cells and human rhabdomyosarcoma cells , human T lymphocytes ) to topoisomerase II inhibitors, microtubule inhibitors, antimetabolites, hydroxyurea and 6-thioguanin, and in vivo (cytarabine and hydroxyurea) treatment resulted not in demethylation but hypermethylation of DNA. Drug-induced DNA hypermethylation could be blocked by pre-exposure to hypomethylating agents administered at nontoxic to mildly toxic concentrations. 48 Acute leukemias 40, 49 and colorectal carcinomas 50 frequently exhibit a methylator phenotype at multiple genomic loci. p15 is both informative for this phenotype in AML 40, 42 and a plausible candidate target for the action of DNA methylation inhibitors, since re-establishment of its inducible expression may reasonably be expected to restore control of blast proliferation in MDS. Prospective analysis of a larger patient series is necessary to determine if in MDS a methylator phenotype is predictive for complete response to methylation inhibitors. Since p15 is unlikely to be the only hypermethylated gene in MDS, establishing other molecular targets of the pharmacologic action of these drugs is important. Their clinical application may not be limited to myeloid neoplasias, and even lower doses may still have demethylating activity. Thus, studies identifying other genes 51 that are hypermethylated in MDS and targeted by demethylating agents are warranted.
